Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma

• DOI: 10.1007/s44178-024-00090-z
• Publication Date: 2024-05-28T05:01:51Z
• Authors: Chaoji Shi; Houyu Ju; Yunteng Wu; Xuhui Ma; Zhiyuan Zhang; Guoxin Ren
• Keywords: Mucosal melanoma; Cyclin-dependent kinase 4

Abstract Mucosal melanoma (MM) is a rare and aggressive form of with poorer prognosis compared to other subtypes. Recent large-scale next-generation sequencing studies, including our own research, have demonstrated that the molecular characteristics potential oncogenic drivers MM differ significantly from those cutaneous melanoma. The emergence selective CDK4/6 inhibitors, already approved for use in breast cancer undergoing phase III clinical trials solid tumors, represents promising development treatment MM. studies shown inhibitors not only induce cell cycle arrest but also play crucial role facilitating interaction between tumor cells host immune system. Moreover, findings indicate dysregulation progression due cyclin‐dependent kinase 4 (CDK4) amplification significant genetic characteristic substantial portion cases. Targeting CDK4 specific patients shows promise precision therapy, utilizing molecularly characterized patient-derived xenograft (PDX) models trials. This paper provides an overview existing literature on MM, as well preclinical investigations combination therapies treatment.